Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,823 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,089 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02556463 | A Study of MEDI9197 in Subjects With Solid Tumors or CTCL and in Combination With Durvalumab and/or Palliative Radiation in Subjects With Solid Tumors | terminated | Phase 1 | 53 | MedImmune LLCINDUSTRY | 3 | Dec 19, 2018 | clinicaltrials |
| NCT03070548 | A Study of Talazoparib in Patients With Advanced Solid Tumors | completed | Phase 1 | 6 | PfizerINDUSTRY | 1 | Dec 17, 2018 | clinicaltrials |
| NCT00390429 |
| Docetaxel and Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors |
| completed |
| Phase 1 / Phase 2 |
| 81 |
| University of California, DavisOTHER |
| 1 |
| Dec 6, 2018 |
| clinicaltrials |
| NCT01332721 | Study of TRC105 Combined With Standard-Dose Bevacizumab for Advanced Solid Tumors for Which Bevacizumab is Indicated | completed | Phase 1 | 38 | Tracon Pharmaceuticals Inc.INDUSTRY | 1 | Dec 5, 2018 | clinicaltrials |
| NCT02966171 | A Dose Escalation Study to Assess the Safety and Tolerability of HMPL-453 in Patients With Advanced Solid Malignancies | terminated | Phase 1 | 14 | Hutchison Medipharma LimitedINDUSTRY | 1 | Nov 21, 2018 | clinicaltrials |
| NCT03747965 | Study of PD-1 Gene-knocked Out Mesothelin-directed CAR-T Cells With the Conditioning of PC in Mesothelin Positive Multiple Solid Tumors | unknown | Phase 1 | 10 | Chinese PLA General HospitalOTHER | 1 | Nov 20, 2018 | clinicaltrials |
| NCT00768469 | Study Evaluating Safety And Tolerability, Solid Tumor | completed | Phase 1 | 10 | Puma Biotechnology, Inc.INDUSTRY | 1 | Nov 19, 2018 | clinicaltrials |
| NCT00629200 | Sodium Stibogluconate With Interferon Alpha-2b for Patients With Advanced Malignancies | completed | Phase 1 | 33 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 15, 2018 | clinicaltrials |
| NCT02214147 | Pharmacokinetics of Alisertib in Adults With Advanced Solid Tumors or Relapsed/Refractory Lymphoma With Varying Degrees of Hepatic Function | completed | Phase 1 | 36 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Nov 15, 2018 | clinicaltrials |
| NCT03731390 | GR1405 Injection in Patients With Advanced Solid Tumor or Lymphoma | unknown | Phase 1 | 30 | Chinese Academy of Medical SciencesOTHER | 1 | Nov 6, 2018 | clinicaltrials |
| NCT00215501 | Capecitabine or 5-Fluorouracil in Combination With Irinotecan and Cisplatin in Patients With Solid Tumor Malignancies | completed | Phase 1 | 54 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 2, 2018 | clinicaltrials |
| NCT02472977 | Safety and Efficacy Study of Ulocuplumab and Nivolumab in Subjects With Solid Tumors(CXCessoR4) | terminated | Phase 1 / Phase 2 | 61 | Bristol-Myers SquibbINDUSTRY | 2 | Nov 1, 2018 | clinicaltrials |
| NCT00096317 | Ixabepilone and Ketoconazole in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | 29 | Montefiore Medical CenterOTHER | 1 | Oct 31, 2018 | clinicaltrials |
| NCT00389805 | Bortezomib and Pemetrexed Disodium in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors | completed | Phase 1 / Phase 2 | 27 | University of California, DavisOTHER | 1 | Oct 31, 2018 | clinicaltrials |
| NCT01714947 | Mass Balance, Pharmacokinetics and Metabolism Study of Alisertib | completed | Phase 1 | 3 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Oct 31, 2018 | clinicaltrials |
| NCT02648425 | Safety and Tolerability of ASLAN001 in Combination With Cisplatin and 5-FU or Cisplatin and Capecitabine | completed | Phase 1 | 31 | ASLAN PharmaceuticalsOTHER | 2 | Oct 25, 2018 | clinicaltrials |
| NCT02366546 | Investigator Initiated Phase 1 Study of TBI-1301 | unknown | Phase 1 | 9 | Mie UniversityOTHER | 1 | Oct 24, 2018 | clinicaltrials |
| NCT00982865 | Trial of MSC1936369B in Subjects With Solid Tumors | completed | Phase 1 | 182 | Merck KGaA, Darmstadt, GermanyINDUSTRY | 4 | Oct 23, 2018 | clinicaltrials |
| NCT02508441 | Phase 1 Safety and Tolerability Study of Andes-1537 for Injection in Patients With Advanced Unresectable Solid Tumors | terminated | Phase 1 | 22 | Andes BiotechnologiesINDUSTRY | 1 | Oct 18, 2018 | clinicaltrials |
| NCT01833546 | A Japanese Phase 1 Trial of TH-302 in Subjects With Solid Tumors and Pancreatic Cancer | completed | Phase 1 | 20 | Merck KGaA, Darmstadt, GermanyINDUSTRY | 1 | Oct 15, 2018 | clinicaltrials |
| NCT00005807 | Treating Patients With Advanced Solid Tumors, Breast Cancer or Recurrent Ovarian Cancer(BMS-247550) | completed | Phase 1 | 40 | Albert Einstein College of MedicineOTHER | 1 | Oct 9, 2018 | clinicaltrials |
| NCT00635778 | A Dose-finding Study of Dalotuzumab in Subjects With Advanced Solid Tumors (MK-0646-002) | completed | Phase 1 | 50 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Oct 9, 2018 | clinicaltrials |
| NCT03496519 | Assessing the Combination of Durvalumab (MEDI4736) and Trabectedin in Solid Tumors | withdrawn | Phase 1 | 0 | University of Colorado, DenverOTHER | 0 | Oct 9, 2018 | clinicaltrials |
| NCT00410553 | Eribulin Mesylate and Gemcitabine Hydrochloride in Treating Patients With Metastatic Solid Tumors or Solid Tumors That Cannot be Removed by Surgery | completed | Phase 1 | 45 | National Cancer Institute (NCI)NIH | 1 | Oct 3, 2018 | clinicaltrials |
| NCT02845414 | Study of CD133KDEL Toxin in the Treatment for Solid Tumors | withdrawn | Phase 1 | 0 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Oct 3, 2018 | clinicaltrials |
| NCT03320525 | Pharmacokinetic Profile of T-ChOS™ in Subjects With Advanced Solid Tumors (CHITIN)(CHITIN) | terminated | Phase 1 | 11 | Herlev HospitalOTHER | 1 | Oct 2, 2018 | clinicaltrials |
| NCT03692520 | Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of SCT200 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 90 | Sinocelltech Ltd.INDUSTRY | 1 | Oct 2, 2018 | clinicaltrials |
| NCT00997360 | Study of PKI-179 Administered Orally to Subjects With Solid Tumors | withdrawn | Phase 1 | 0 | Wyeth is now a wholly owned subsidiary of PfizerINDUSTRY | 0 | Sep 27, 2018 | clinicaltrials |
| NCT00742105 | Phase I Study to Determine the Maximum Tolerate Dose (MTD) of BGT226 in Advanced Solid Tumors in Japan | terminated | Phase 1 | 18 | Novartis PharmaceuticalsINDUSTRY | 1 | Sep 25, 2018 | clinicaltrials |
| NCT02442531 | A Study of CriPec® Docetaxel Given to Patients With Solid Tumours(NAPOLY) | completed | Phase 1 | 33 | Cristal TherapeuticsINDUSTRY | 2 | Sep 24, 2018 | clinicaltrials |
| NCT01971515 | First-in-Human Dose Escalation Trial in Subjects With Advanced Malignancies | completed | Phase 1 | 101 | EMD SeronoINDUSTRY | 1 | Sep 19, 2018 | clinicaltrials |
| NCT03628131 | Combination Chemotherapy With Pazopanib in Children and Adolescents With Relapsed/Refractory Solid Tumors | unknown | Phase 1 / Phase 2 | 46 | Samsung Medical CenterOTHER | 1 | Sep 19, 2018 | clinicaltrials |
| NCT01497925 | Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer | completed | Phase 1 | 43 | Polaris GroupINDUSTRY | 1 | Sep 13, 2018 | clinicaltrials |
| NCT00004863 | Paclitaxel and GEM 231 in Treating Patients With Recurrent or Refractory Solid Tumors | completed | Phase 1 | 18 | Montefiore Medical CenterOTHER | 1 | Sep 10, 2018 | clinicaltrials |
| NCT00004864 | Docetaxel and GEM 231 in Treating Patients With Recurrent or Refractory Solid Tumors | completed | Phase 1 | — | Montefiore Medical CenterOTHER | 1 | Sep 10, 2018 | clinicaltrials |
| NCT02650635 | TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors | terminated | Phase 1 | 4 | Mayo ClinicOTHER | 1 | Sep 5, 2018 | clinicaltrials |
| NCT00003713 | Chemotherapy in Treating Patients With Advanced or Metastatic Solid Tumors | completed | Phase 1 | 35 | Genzyme, a Sanofi CompanyINDUSTRY | 2 | Aug 29, 2018 | clinicaltrials |
| NCT00003822 | SR-45023A in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | 30 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Aug 29, 2018 | clinicaltrials |
| NCT00004049 | SR-45023A in Treating Patients With Locally Advanced or Metastatic Solid Tumors | completed | Phase 1 | 36 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Aug 29, 2018 | clinicaltrials |
| NCT00878111 | Study of NGR-hTNF Administered at High Doses in Patient With Advanced or Metastatic Solid Tumour | completed | Phase 1 | 48 | AGC Biologics S.p.A.INDUSTRY | 1 | Aug 29, 2018 | clinicaltrials |
| NCT01438554 | Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma | completed | Phase 1 | 89 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Aug 29, 2018 | clinicaltrials |
| NCT02225002 | Phase 1, Open-Label, Dose-Escalation Study of CP-870,893 in Patients With Solid Tumors | completed | Phase 1 | — | Abramson Cancer Center at Penn MedicineOTHER | 1 | Aug 28, 2018 | clinicaltrials |
| NCT00960063 | A Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Pediatric Participants With Advanced Solid Tumors (P05883, MK-7454-006) | terminated | Phase 1 | 4 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 27, 2018 | clinicaltrials |
| NCT01463696 | Study of Safety and Pharmacokinetics of MK-8242 in Participants With Advanced Solid Tumors (P07650) | terminated | Phase 1 | 48 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 27, 2018 | clinicaltrials |
| NCT02492477 | TOP-TRIAL Safety of Not Flushing Non-used PORT-A-CATH® in Cancer Patients | terminated | Phase 1 | 4 | Krankenhaus Barmherzige Schwestern LinzOTHER | 1 | Aug 21, 2018 | clinicaltrials |
| NCT03330990 | Evaluate the Effect of Entrectinib on the Pharmacokinetics of Midazolam in Cancer Patients | completed | Phase 1 | 15 | Hoffmann-La RocheINDUSTRY | 1 | Aug 21, 2018 | clinicaltrials |
| NCT01907802 | Dabrafenib in Treating Patients With Solid Tumors and Kidney or Liver Dysfunction | terminated | Phase 1 | 8 | National Cancer Institute (NCI)NIH | 2 | Aug 14, 2018 | clinicaltrials |
| NCT00706030 | Study Evaluating Neratinib (HKI-272) In Combination With Vinorelbine In Subjects With Solid Tumors And Metastatic Breast Cancer | completed | Phase 1 / Phase 2 | 92 | Puma Biotechnology, Inc.INDUSTRY | 11 | Aug 9, 2018 | clinicaltrials |
| NCT00701103 | Dose Escalation Trial of Dalotuzumab (MK-0646) in Advanced Solid Tumors and Multiple Myeloma (MK-0646-001) | completed | Phase 1 | 80 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 8, 2018 | clinicaltrials |
| NCT03615313 | PD-1 Antibody Expressing mesoCAR-T Cells for Mesothelin Positive Advanced Solid Tumor(PAEMCMPAST) | unknown | Phase 1 / Phase 2 | 50 | Shanghai Cell Therapy Research InstituteOTHER | 1 | Aug 3, 2018 | clinicaltrials |
Data updated 24 days agoSource updated Dec 19, 2018source: clinicaltrials